TauRx Therapeutics Ltd, 2017-12-01: Registry record for a phase 3 trial of TRx0237 at 8 or 16 mg/day versus placebo in 598 patients with Alzheimer's disease, with a delayed-start open-label phase. Primary completion 2022-03-31, study completion 2023-04-04, results posted on the registry.
The purpose of this study is to determine the safety and efficacy of TRx0237 16 mg/day and 8 mg/day in the treatment of subjects with Alzheimer's Disease compared to placebo.
registry record
TauRx Therapeutics Ltd, 2017-12-01: Registry record for a phase 3 trial of TRx0237 at 8 or 16 mg/day versus placebo in 598 patients with Alzheimer's disease, with a delayed-start open-label phase. Primary completion 2022-03-31, study completion 2023-04-04, results posted on the registry. Record field transcription from the registry entry (labelled a record field, confidence MEDIUM). Interventional, randomised, double-blind, placebo-controlled with delayed-start open-label extension, phase 3. N=598 actual. Country: 76 sites in North America and Europe. Dose: 16 mg/day or 8 mg/day oral (4 mg tablets twice daily). Comparator: placebo, some containing a urinary discolorant. Sponsor: TauRx Therapeutics Ltd; company employees and officers are authors on the design paper (Wischik et al., J Prev Alzheimers Dis 2022, PMID 36281683). Doses are 8-16 mg/day of the reduced form, three orders of magnitude below the milligram-per-kilogram IV doses discussed in the source's protocols. Registry status: COMPLETED. No direct PDF exists for a registry record; source_url is the canonical study page. Also filed as MTC-093, MTK-22 (claims C3, C8, F1).
